Back to results

Mouse anti-human melanoma associated antigen (clone pnl2)

- this new monoclonal antibody is directed against a new fixative resistant melanocyte/melanoma-associated antigen. - PNL2 labels more than 70% of neoplastic cells in all primary melanomas irrespective of their histologic type. All metastatic melanomas are also stained
Interest / Relevance: - diagnosis of primary and metastatic melanomas
Keywords: null
Scientist's name: Georges DELSOL
Laurence LAMANT-ROCHAIX,Mohamad Talal AL SAATI
Publications:
PNL2 a new monoclonal antibody directed against a fixative-resistant melanocyte antigen. Rochaix P Lacroix-Triki M Lamant L Pichereaux C Valmary S Puente E Al Saati T Monsarrat B Susini C Buscail L Delsol G Voigt JJ. Mod Pathol. 2003 May;16(5):481-90.

Reference:

RT00377

Business Developper
contact
Inserm Transfert
Research Tools
Clones available: PNL2
null
Isotype: null
null
Source: null
null
Specificity: null
Immunogen Seq ID: Somatostatin receptor subtype 2 recombinant protein (probably a mouse melanocyte auto-antibody)
Cellular Distribution: Skin and oral mucosae melanocytes, Reacts with granulocytes when used at high concentration.
Know Cross Reactivity: granulocytes. PNL2,stained most of the clear cell sarcoma cells, and a few cells in angiomyolipomas
Depositor: null
FBS: 15%
Rare disease: No
Last update: 18/06/2024

You might also be interested in

BIO18523-D2

Test debug

TEST […]

Read more
BIO21469-T1

Use of irap inhibitors for the treatment of

Upon activation, mast cells rapidly release preformed inflammatory mediators from large cytoplasmic […]

Read more
BIO20499-T1

Safety and efficacy of mait cells for adoptive

The inventors explored in an allogeneic situation the regulatory potential of Mucosal-Associated […]

Read more
BIO21500-T1

Intestinal cathelicidin antimicrobial peptide

The present invention relates to the treatment of autoimmune diseases. The inventors determined that […]

Read more
BIO17083-T1

Use of hedgehog inhibitors for the treatment of

The inventors demonstrate for the first time the activation of the Hedgehog (HH) signaling pathway […]

Read more
BIO20418-T1

Methods for the diagnosis and thetreatment of

The invention relates to methods for the prediction and the treatment of risk of acute graft versus […]

Read more
BIO60360-T1

Fc-engineered anti-human ige antibodies and

The present invention relates to the treatment of IgE-mediated disease. The inventors hypothesized […]

Read more
BIO21335-T1

Use of etv3 or etv6 inhibitors for blocking the

In inflamed tissues, monocytes differentiate into macrophages (mo-Mac) or dendritic cells (mo-DC). […]

Read more
BIO17668-T1

Methods for modulating innate lymphoid cell

The present invention relates to methods for modulating innate lymphoid cell activity, antibody drug […]

Read more
BIO22067-T1

Use of tcr-deficient car-tregs in combination with

The present invention is defined by the claims. In particular, the present invention relates to the […]

Read more